The study will start now and run in parallel with Recce’s Indonesian Phase 3 trial, which remains on track to commence shortly. This program does not impact the initiation timeline of the ...

This approval will allow up to 20 additional patients to access RECCE® 327 Topical Gel (R327G) under the existing open-label study protocol. R327G has attracted strong interest from investigators ...

In a strong validation of the company’s clinical pipeline, Recce Pharmaceuticals has secured $5 million via a share placement with a private, Australian-based investor. The company has also ...

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor ...

Recce Pharmaceuticals is commercializing a novel synthetic broad-spectrum antibiotic designed to overcome antimicrobial resistance. Its lead compound, RECCE 327, is one of the first entirely new ...

Recce secures A$5M from private investor and launches A$10.8M entitlement offer to fund Phase III topical clinical trials The smart money in medicine: the silent pandemic Recce Pharmaceuticals ...

SYDNEY, April 23, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), a leading developer of a new class of synthetic anti-infectives, today announced ...

Recce Pharmaceuticals receives Human Research Ethics Committee approval to expand its phase II clinical trial following positive results. Follows recently released positive Phase II clinical trial ...